Affinivax, Astellas begin clinical quest to beat Pfizer's Goliath with a new kind of pneumococcal vaccine
Days after the FDA blessed Merck’s effort to challenge Pfizer’s mega-blockbuster Prevnar 13 with a breakthrough designation, Affinivax is making the leap into the clinic with its own take on the pneumococcal vaccine.
It’s no small feat for a biotech player that got started with $4 million in seed funding from the Gates Foundation in 2014 and has been running purely on grants as well as partnership dollars from Astellas — which is shouldering much of clinical work in the Phase I/II study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.